Literature DB >> 12828887

[Outcomes and clinical characteristics of patients with pulmonary fibrosis and respiratory failure admitted to an intensive care unit. A study of 20 cases].

María Molina-Molina1, Joan Ramon Badia, Alejandra Marín-Arguedas, Antoni Xaubet, María José Santos, José María Nicolás, Miguel Ferrer, Antoni Torres.   

Abstract

BACKGROUND AND
OBJECTIVE: Previous reports on the outcome of patients with pulmonary fibrosis admitted to the intensive care unit (ICU) suggest a bad prognosis. The aim of our study was to evaluate the course and prognosis of patients with pulmonary fibrosis admitted to the ICU of our hospital because of acute respiratory failure. PATIENTS AND
METHOD: Retrospective, case-series, observational study. We evaluated the clinical records of patients with pulmonary fibrosis referred to the intensive care unit in a tertiary university teaching hospital between January 1986 and June 2002. Complete information on the diagnosis and clinical course of the pulmonary disease, pulmonary function tests, current clinical status, ventilatory support and adjunctive therapies applied in the ICU, length of stay and mortality was collected.
RESULTS: Twenty patients were included, 14 with idiopathic pulmonary fibrosis and 6 with pulmonary fibrosis and associated collagen vascular diseases. The mean (SD) interval between the diagnosis of fibrosis and the admission to ICU was 14 (20) months. All patients presented with severe acute respiratory failure (PaO2/FiO2 < 200). The cause of clinical worsening was identified in 8 (40%) cases (5 bacterial and 3 fungal infections). In the ICU, 17 patients required mecanical ventilation. All patients worsened progressively, with refractory hypoxemic respiratory failure (100%) and hemodynamic instability after endotraqueal intubation (70%). Mechanical ventilation was associated with a 100% mortality.
CONCLUSION: An identifiable cause of acute respiratory failure could not be found in a significant proportion of patients despite a systematic work-up. Mechanical ventilation and aggressive life support measures do not seem to provide any further benefit in patients with pulmonary fibrosis and severe respiratory failure.

Entities:  

Mesh:

Year:  2003        PMID: 12828887     DOI: 10.1016/s0025-7753(03)73856-1

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  6 in total

1.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

2.  Bone marrow-derived cells participate in stromal remodeling of the lung following acute bacterial pneumonia in mice.

Authors:  Vladimir B Serikov; Viatcheslav M Mikhaylov; Anna D Krasnodembskay; Michael A Matthay
Journal:  Lung       Date:  2008-03-21       Impact factor: 2.584

Review 3.  Acute exacerbation of idiopathic pulmonary fibrosis: lessons learned from acute respiratory distress syndrome?

Authors:  Alessandro Marchioni; Roberto Tonelli; Lorenzo Ball; Riccardo Fantini; Ivana Castaniere; Stefania Cerri; Fabrizio Luppi; Mario Malerba; Paolo Pelosi; Enrico Clini
Journal:  Crit Care       Date:  2018-03-23       Impact factor: 9.097

4.  Pulmonary fibrosis induced by H5N1 viral infection in mice.

Authors:  Jian Qiao; Miaojie Zhang; Jianmin Bi; Xun Wang; Guangcun Deng; Guimei He; Zhihua Luan; Nana Lv; Tong Xu; Lihong Zhao
Journal:  Respir Res       Date:  2009-11-12

5.  The Efficacy and Safety of Chemotherapy in Patients With Nonsmall Cell Lung Cancer and Interstitial Lung Disease: A PRISMA-Compliant Bayesian Meta-Analysis and Systematic Review.

Authors:  Yu Jie Chen; Ling Xiao Chen; Mei Xiang Han; Tian Song Zhang; Zhi Rui Zhou; Dian Sheng Zhong
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

Review 6.  Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights.

Authors:  Paola Faverio; Federica De Giacomi; Luca Sardella; Giuseppe Fiorentino; Mauro Carone; Francesco Salerno; Jousel Ora; Paola Rogliani; Giulia Pellegrino; Giuseppe Francesco Sferrazza Papa; Francesco Bini; Bruno Dino Bodini; Grazia Messinesi; Alberto Pesci; Antonio Esquinas
Journal:  BMC Pulm Med       Date:  2018-05-15       Impact factor: 3.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.